These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 11106715

  • 1. Peginterferon alfa-2a in patients with chronic hepatitis C.
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ.
    N Engl J Med; 2000 Dec 07; 343(23):1666-72. PubMed ID: 11106715
    [Abstract] [Full Text] [Related]

  • 2. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J.
    N Engl J Med; 2000 Dec 07; 343(23):1673-80. PubMed ID: 11106716
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C, AIDS Clinical Trials Group A5071 Study Team.
    N Engl J Med; 2004 Jul 29; 351(5):451-9. PubMed ID: 15282352
    [Abstract] [Full Text] [Related]

  • 6. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team.
    N Engl J Med; 2009 Apr 30; 360(18):1839-50. PubMed ID: 19403903
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team.
    N Engl J Med; 2010 Apr 08; 362(14):1292-303. PubMed ID: 20375406
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
    Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, Flisiak R, Rehak V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG.
    Hepatology; 2008 Aug 08; 48(2):407-17. PubMed ID: 18666223
    [Abstract] [Full Text] [Related]

  • 11. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.
    N Engl J Med; 2005 Jun 30; 352(26):2682-95. PubMed ID: 15987917
    [Abstract] [Full Text] [Related]

  • 12. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
    Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S.
    Hepatology; 2007 Sep 30; 46(3):640-8. PubMed ID: 17879366
    [Abstract] [Full Text] [Related]

  • 13. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
    Perry CM, Jarvis B.
    BioDrugs; 2002 Sep 30; 16(3):213-7. PubMed ID: 12102649
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
    Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, Hepatitis Interventional Therapy Group.
    Hepatology; 2001 Aug 30; 34(2):395-403. PubMed ID: 11481625
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.
    Jensen DM, Marcellin P.
    Eur J Gastroenterol Hepatol; 2005 Sep 30; 17(9):899-904. PubMed ID: 16093865
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.